Reuters logo
9 months ago
BRIEF-Adverum Biotechnologies provides update on Alpha-1 antitrypsin deficiency program
October 14, 2016 / 11:37 AM / 9 months ago

BRIEF-Adverum Biotechnologies provides update on Alpha-1 antitrypsin deficiency program

1 Min Read

Oct 14 (Reuters) - Adverum Biotechnologies Inc :

* Adverum Biotechnologies provides update on alpha-1 antitrypsin deficiency program

* Expects to begin enrolment of patients in phase 1/2 clinical trial for advm-043 in Q4 of 2017.

* Adverum Biotechnologies Inc - decided to upgrade advm-043 manufacturing process by implementing its proprietary baculovirus-based production system

* Adverum Biotechnologies Inc - company now expects to begin enrolment of patients in phase 1/2 clinical trial for advm-043 in Q4 of 2017

* Plans to transfer third-party contract manufacturing for advm-043 to a large-scale contract manufacturer

* Adverum Biotechnologies Inc - goal is to meet with FDA to review modified plans in Q1 of 2017

* Adverum Biotechnologies - other lead programs for wamd and hae remain on target to initiate toxicology studies in first half of 2017 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below